Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the ‘International Collaboration of the Year’ category.

THE awards nomination poster, with the text: Shortlisted Times Higher Education Awards 2017, International collaboration of the year

Known as the ‘Oscars of higher education’, the THE Awards recognise “the talent, dedication and innovation of individuals and teams across all aspects of university life”. The ‘International Collaboration of the Year’ category acknowledges “exceptional projects carried out jointly between a UK institution and one or more international partners”.

WWARN is a collaborative research network that works to provide the information necessary to optimise antimalarial treatments, in turn, reducing the number of people falling ill and dying from malaria. WWARN works with over 260 collaborators across the world. The Network is part of the Infectious Diseases Data Observatory (IDDO) (link is external), based at the University of Oxford.

The nomination recognises the results of two research projects that have led to international policy changes to help improve the outcomes of those treated with an important antimalarial medicine, dihydroartemisinin-piperaquine (DP).

The full story is available on the WWARN website

Similar stories

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Dengue Research Article Awarded The 2021 – 2022 Alexandre Yersin Prize for Outstanding Publications

OUCRU research article titled ‘Combination of inflammatory and vascular markers in the febrile phase of dengue is associated with more severe outcomes’ was recently awarded the 2021-2022 Alexandre Yersin Prize for Outstanding Publications.

Registration is open for The Global Health Network Conference 2022

To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.

Gail Carson chair of GOARN

Dr Gail Carson from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is nominated chair of WHO Global Outbreak Alert & Response Network (GOARN)

RECOVERY trial celebrates two-year anniversary of life-saving dexamethasone result

Two years ago, the RECOVERY trial gave the world its first breakthrough against coronavirus: the discovery that an inexpensive steroid pill, dexamethasone, reduced deaths by up to a third from COVID-1. Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.